Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience

Anthony A. Oliva | Lisa McClain-Moss | Andrea Pena | Amy Drouillard | Joshua M. Hare

Abstract

Extraordinary advances in medicine and public health have contributed to increasing life expectancy worldwide. However, health span—"healthy aging"—has paradoxically lagged to parallel this increase. Consequently, aging-associated illnesses, such as Alzheimer's disease and aging frailty, are having a growing impact on patients, their families, and entire health-care systems. Typically, such disorders have been treated as isolated disease entities. However, the inextricable links between aging-associated disorders and the aging process itself have become increasingly recognized, leading to formation of the field of geroscience. The geroscience concept is that treating the aging process itself should lead to treatment and prevention of aging-related disorders. However, the aging process is complex, dictated by highly interrelated pleiotropic processes. As such, therapeutics with pleiotropic mechanisms of action (either alone, or as part of combinatorial strategies) will be required for preventing and treating both aging and related disorders. Mesenchymal stem cells (MSCs) have multiple mechanisms of action that make these highly promising geroscience therapeutic candidates. These cells have a high safety profile for clinical use, are amenable to allogeneic use since tissue-type matching is not required, and can have sustained activity after transplantation. Herein, we review preclinical and clinical data supporting the utility of allogeneic MSCs as a geroscience therapeutic candidate.

Keywords

geroscience, mesenchymal stem cell, regenerative medicine

1 | INTRODUCTION

The interdisciplinary field of geroscience is aimed at understanding the relationship between the biology of aging and aging-related disorders. The central tenant, the "geroscience hypothesis," is both simple and profound: targeting aging will delay the emergence, and diminish the severity, of many chronic diseases because the major underlying risk factor for these diseases is aging.1
important candidates for meeting many of the requisites as a pleiotropic intervention (Table 1).

The geroscience potential of MSCs resides in their intrinsic properties.5-15 MSCs have powerful anti-inflammatory properties and home to sites of injury and inflammation, and are thus ideal candidates for treating aging-related inflammation (also referred to as “inflammaging”).16 MSCs: secrete numerous bioactive molecules that stimulate endogenous stem cell recruitment, proliferation, and differentiation; inhibit apoptosis and fibrosis; can, to an extent, differentiate in vivo to contribute to repair and regeneration; have the potential to improve immune function; and promote neovascularization. MSCs can also regulate host stem cell niches through paracrine activity and cell-cell interactions to promote intrinsic repair and regenerative responses.17-20

Mesenchymal stem cells possess important immunoprivileged/immunoevasive properties, thereby rendering them safe for allogeneic use. This results from MSCs having undetectable levels of major histocompatibility complex (MHC) class II molecules, and low-level MHC class I expression.19,21 Even xenogeneic grafts of human MSCs into immunocompetent rodent, dog, goat, baboon, and swine do not evoke anti-allograft response.11 Thus, MSCs have the potential to be an “off-the-shelf” therapy that is immediately available and accessible to broad patient populations.

Allogeneic MSCs have a demonstrated high clinical safety profile,19,20,22 and benefits from a single infusion of MSCs can persist for months.17,18,20,23-25 Furthermore, multiple dosing is well-tolerated, and human MSCs can persist for over a month in immunocompetent hosts, thereby helping to explain their sustained beneficial effects.17,18,20,22-26 MSCs have also been shown to not undergo malignant transformation after transplantation into patients.25 A comprehensive meta-analysis of 36 clinical studies entailing 1024 volunteers (either healthy or with a clinical condition) supports the concept that MSC treatment has an exceptionally high safety profile.20

Since MSCs can be used as an allogeneic treatment, they can be sourced from young healthy donors. Such sourced MSCs can provide significantly higher potency over similarly prepared autologous MSCs.14,27-30 This likely is due to the fact that autologous MSCs, being used in the context of treating aging, can be impaired by advanced age and/or patient comorbidity.31,32 Relative to young and middle-aged adults, MSCs from elderly adults appear to have reduced regenerative potential, as indicated by diminished proliferative capacity, diminished differentiation potential, increased senescence, increased expression of DNA-break repair genes, altered DNA-methylation and gene-expression patterns, impaired migration, altered expression of microRNAs and cell-surface markers, and diminished anti-inflammatory activity.33-41

### Table 1 Geroscience application of allogeneic MSCs

| Pillars of aging | Hallmarks of aging | Potential benefits of MSCs |
|------------------|--------------------|---------------------------|
| Inflammation     |                    | Inhibit pro-inflammatory pathways | Stimulate anti-inflammatory pathways |
| Stem cell and regeneration impairment | Stem cell exhaustion | Replenish exhausted MSCs | Promote intrinsic regenerative and repair responses | Reduce cellular senescence |
| Stress maladaptation | Altered intercellular communication | Potential to renormalize stress response |
| Epigenetics alterations | Epigenetics alterations | Unknown |
| Macromolecular damage | Genomic instability | Reduce DNA damage | Reduce oxidative stress |
| Metabolic dysfunction | Nutrient sensing dysregulation | Mitochondrial exchange | Reduce oxidative stress |
| Proteostasis dysfunction | Proteostasis dysfunction | Potential to stimulate proteostatic responses |

Abbreviation: MSCs, mesenchymal stem cells.

### 2 | PRECLINICAL EVIDENCE DEMONSTRATING THE POTENTIAL OF ALLOGENEIC MSCS TO IMPROVE HEALTH SPAN AND LIFE EXPECTANCY

Preclinical studies support the efficacy of allogeneic MSCs as a geroscience-directed therapeutic. In one of the earliest studies to examine this, mice aged 18-24 months were transplanted with allogeneic bone marrow stem cells (which contain a mixture of MSCs and other stem cell types).42 Those mice transplanted with stem cells from young donor mice (1-2 months old) had a 16% increase in average life expectancy, and a substantial decline in age-related bone density deterioration. Such benefits were not imbued using MSCs sourced from old donors (from 20-24 month-old mice). A caveat to this study is that all animals underwent X-irradiation (500 cGy) prior to transplantation of the stem cells, which would appear confounding in terms of relating the results to an understanding of treating the aging process. Nevertheless, the results are encouraging and provide rationale for further study.

In more direct experiments to evaluate the potential of allogeneic MCSs for aging, transplantation of young normal mouse MSCs into premature-aging-model mice (Bmi-1-deficient) were performed using a multi-dosing paradigm.43 The transplanted MSCs promoted growth in the treated mice, which was not seen with vehicle control, and led to significant improvements in life span (>100% increase over
untreated mice). This was accompanied by migration of the MSCs to multiple organs and differentiation into multiple cell types, and inhibition of cellular senescence normally seen in the Bmi-1-deficient mice. Moreover, bone osteogenesis was improved and bone adipogenesis reduced, with concomitant reduction in osteoporosis. Immune status also improved. Furthermore, oxidative stress and DNA damage in multiple organs were broadly reduced. Cumulatively, these results suggest the pleiotropic potential of allogeneic MSCs to treat aging and aging-associated diseases.

In yet another study, 18-month-old mice were given single or multiple intravenous infusions (four infusions at 2-week intervals) of human MSCs. The treated mice showed significant improvements in locomotion, and behavioral/cognitive performance improved as assessed via passive avoidance and the Morris water maze. Impressively, these improvements approached those of normal young mice (8-weeks old). Furthermore, treated mice showed improved hippocampal cell count.

Reproductive potential of old female mice could also be significantly improved after receiving regular transplants of MSCs derived from young mice. Impressively, offspring survival also improved. It is interesting to note that these results were more profound when MSCs derived from young female mice were used, compared to male donor mice. In another murine study, allogeneic transplant of MSCs reversed aging-associated dysregulation of the gastrointestinal immune system. In these studies, aged mice (>18 months old) that received transplanted MSCs showed improved levels of mucosal secretory IgA and plasma IgG antibody production that restored nearly to levels of young mice. Moreover, bone osteogenesis was improved and bone adipogenesis reduced, with concomitant reduction in osteoporosis. Immune status also improved. Furthermore, oxidative stress and DNA damage in multiple organs were broadly reduced. Cumulatively, these results suggest the pleiotropic potential of allogeneic MSCs to treat aging and aging-associated diseases.

3 | CLINICAL EVALUATION OF ALLOGENEIC MSCS FOR AGING-RELATED INDICATIONS

There are currently over 250 clinical trials for use of allogeneic MSCs reported on https://clinicaltrials.gov (as of August 8, 2019). Given the pleiotropic mechanisms of action of these cells, it is not surprising that the vast majority of these trials are for aging-related conditions (eg, the metabolic syndrome, cardiac indications, osteoarthritis, autoimmune disorders, and type II diabetes). Three of these studies are for aging frailty (accession numbers NCT02065245, NCT02992915, and NCT03169231), which can be considered an extreme form of unsuccessful aging.

Aging frailty is a biologically driven decline in function and reserves across multiple physiologic systems that appears independent of the chronological aging process. The biological basis of aging frailty appears multifaceted and includes an aging-related chronic systemic inflammatory state known as "inflammaging." This loss of physiological control over inflammation appears resultant from an imbalance between the levels of pro- and anti-inflammatory cytokines, as well as diminished capacity to restore equilibrium once an inflammatory stimulus has subsided. The ultimate result is elevated serum levels of pro-inflammatory cytokines and diminished serum levels of anti-inflammatory cytokines (eg, tumor necrosis factor [TNF]-α and interleukin-10, respectively).

Subjects with aging frailty are exceptionally compromised in their ability to cope with everyday or acute stressors. This leads to increased vulnerability to disease and injury (eg, increased adverse clinical outcomes, such as falls, fractures, infections, hospitalizations, institutionalizations, and mortality). As a result of aging frailty, normally small insults (eg, minor infection, minor surgery, tolerance for a new drug) result in dramatic and disproportionately severe adverse consequences, frequently leading to a spiral of decline. From a clinical standpoint, aging frailty is characterized by weakness, weight loss, slowness, and low activity, as well as chronic inflammation as described above. A conservative estimate for the prevalence of aging frailty is 10% of those aged 65 years and older. This prevalence will continue to increase with changing demographics towards a more elderly population. Given the important consequences, leading geriatric researchers, including Linda Fried, John Morley, Kenneth Rockwood, and Jeremy Walston, have recommended that everyone aged 70 years and older should be evaluated for frailty using the simple, validated frailty assessment tools available.

The first-in-human clinical study using allogeneic MSCs as an intervention for aging frailty was recently completed, called the "CRATUS study" ("Allogeneic Human Mesenchymal Stem Cells [hMSC] in Patients With Aging FRAilTy Via Intravenous Delivery"; NCT02065245). CRATUS was a safety study consisting of two phases in which subjects with aging frailty were intravenously infused with either allogeneic MSCs or placebo. Phase 1 was an open-label dose-escalation study in which each subject was given a single dose of 20 million MSCs, 100 million MSCs, or 200 million MSCs. The treatments were found to be safe and well-tolerated at all dosages (eg, there were no reported adverse events or serious adverse events related to the cells, and no observed immunoreactions against the product as assessed by anti-human leukocyte antigen [anti-HLA] antibody production). Despite the trial only being powered for safety, there were also statistically significant improvements in several key measures of effect. These included decreased inflammatory status, such as a significant decrease in TNF-α; and improved physical functioning, as assessed by the 6-minute walk test and spirometry. These phase 1 measures were then prospectively tested in a small placebo-controlled, randomized, double-blinded phase 2 trial. The cells were again found to be safe and led to similar significant improvements in key effect measures of aging frailty.

Combined, the phase 1/2 results of the CRATUS study can be summarized as follows: (a) allogeneic MSCs were safe and well-tolerated when administered to aging frailty subjects; (b) allogeneic MSC treatment led to statistically significant improvements in key measures of aging frailty, including decreasing inflammation and improving physical performance; and (c) none of the evaluated safety or effect measures showed...
worsening. While not significant, there also appeared to be a trending decrease overall in incidents of serious adverse events with MSC treatment relative to placebo. Based on the promising results of CRATUS, a larger phase 2b study is now being conducted (NCT03169231). This trial consists of five treatment arms (25 million, 50 million, 100 million, or 200 million allogeneic MSCs, or placebo), is powered for effect based on the 6-minute walk test, and is currently enrolling. A second related study to evaluate the potential of allogeneic MSCs to improve immune status in subjects with aging frailty is also being conducted (NCT02982915).

4 | CONCLUSION

Worldwide demographics continue to shift towards populations with increased life expectancy. Consequently, the importance of achieving a health span that parallels those changes has become paramount. A geroscience approach offers promise towards achieving these goals, by treating the aging process itself. Given the complex and multifactorial nature of the biology aging, a multimodal approach is required. As presented herein, there is strong evidence suggesting the high potential of allogeneic MSCs as a geroscience therapeutic due to their pleiotropic mechanisms of action. Animal models have shown that allogeneic MSCs can successfully treat many aspects of the aging process, and lead to significant improvements in life expectancy with accompanying increases in health span. Clinical evaluation from early stage trials supports the promise of allogeneic MSCs to successfully treat aging frailty. Ultimately, this regenerative medicine approach could be extended to examine whether MSC can be used to prevent aging frailty and for treating aging in general. Given the high safety profile of allogeneic MSCs, these studies would appear to be the imminent next steps.

ACKNOWLEDGEMENTS

We thank the following agencies for their generous support of this work: the Alzheimer’s Association through the Part the Cloud Challenge on Neuroinflammation (grant awards #PTC C-16-422443 and PTC-CS-19-623225); the National Institute of Aging/National Institutes of Health (awards 1R44AG062015-01, 4R44AG062015-02, 1R42AG054322-01A1 and 4R42AG054322-02); and the Maryland Stem Cell Research Foundation (MSCRF) TEDCO (grant award 2018-MSCRFCL-4346).

CONFLICTS OF INTEREST

All authors are affiliated with Longeveron LLC, either as full-time employees or consultants. Dr. Hare reported having a patent for cardiac cell-based therapy. He holds equity in Vestinon Inc. and maintains a professional relationship with Vestinon Inc. as a consultant and member of the Board of Directors and Scientific Advisory Board. Dr. Joshua Hare is the Chief Scientific Officer, a compensated consultant and advisory board member for Longeveron and holds equity in Longeveron. He is also the co-inventor of intellectual property licensed to Longeveron.

ORCID

Anthony A. Oliva https://orcid.org/0000-0002-3099-2421
Joshua M. Hare https://orcid.org/0000-0002-7751-5032

REFERENCES

1. Sierra F, Kohanski R. Geroscience and the trans-NIH Geroscience Interest Group. G3G. Geroscience. 2017;39(1):1-5.
2. Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and dementia: an international consensus statement. J Alzheimers Dis. 2018;62(2):561-570.
3. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-713.
4. Lopez-Otin C, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-713.
5. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009;13(9B):3103-3109.
6. Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev. 2012;133(6):456-466.
7. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64(11):1183-1189.
8. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57(5):M326-M332.
9. Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009;22(3):819-827.
10. Tay L, Lim WS, Chan M, Ye RJ, Chong MS. The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease. J Nutr Health Aging. 2016;20(3):288-299.
11. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014;6(5):526-539.
12. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012;5:19.
13. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011;27(1):79-87.
14. Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015;2(5):467-475.
15. Asok K, Tsruhara A, Takagaki K, et al. Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice. PLoS ONE. 2016;11(2):e0148185.
16. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(suppl 1):S4-S9.
17. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011;108(7):792-796.
18. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):913-922.
19. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579-1586.
20. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.

21. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57.

22. Schuleri KH, Feigenbaum GS, Centola M, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009;30(22):2722-2732.

23. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379.

24. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA. 2009;106(33):14022-14027.

25. von Bahr L, Batsis J, Moll G, et al. Analysis of tissues following mesenchymal stem cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575-1578.

26. Golpanian S, DiFede DL, Pujol MV, et al. Rationale and design of the human allogeneic mesenchymal stem cells (hMSC) in patients with aging FRAIITY via intravenoUS delivery (CRATUS) study: a phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. Oncotarget. 2016;7(1):11899-11912.

27. Kissel CK, Lehrmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarct heart failure. J Am Coll Cardiol. 2007;49(24):2341-2349.

28. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45(9):1441-1448.

29. Kovacic JC, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. Circulation. 2011;123(15):1650-1660.

30. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol. 2010;660:65-84.

31. Kinkaid HY, Huang XP, Li RK, Weisel RD. What’s new in cardiac cell therapy? Allogeneic bone marrow stromal cells as "universal donor cells". J Card Surg. 2010;25(3):359-366.

32. Seals DR, Justice JN, LaRocca TJ. Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity. J Physiol. 2016;594(8):2001-2024.

33. Alt EU, Senst C, Murthy SN, et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res. 2012;8(2):215-225.

34. Beane OS, Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS ONE. 2014;9(12):e115963.

35. Bustos ML, Huleihel L, Kapetanaki MG, et al. Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response. Am J Respir Crit Care Med. 2014;189(7):787-798.

36. Hermann A, List C, Habisch HJ, et al. Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. Cytotherapy. 2010;12(1):17-30.

37. Liu M, Lei H, Dong P, et al. Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties. Cell Transplant. 2017;26(9):1505-1519.